IDXX stock forecast, quote, news & analysis
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock... Show more
IDEXX Laboratories (IDXX) Stock Analysis: Diagnostics Leader Rebounds Toward $560 Ahead of Q3 Earnings
Key Takeaways
- IDEXX Laboratories shares have climbed roughly 9% over the trailing month, recovering from a September pullback that pushed the stock toward its 52-week low near $500.
- The latest available price of about $557.97 remains well below the 52-week high of $769.98, reflecting a still-cautious tape despite the recent rebound.
- Second-quarter results topped expectations, with revenue rising 9.7% year over year and management raising full-year guidance.
- Analysts remain broadly constructive, with Jefferies reiterating a Buy rating while preferring IDEXX's diagnostics model over animal-health pharma peers.
- Third-quarter results are scheduled for November 2, 2026, making the upcoming print a key near-term catalyst.
Current Market Snapshot
IDEXX Laboratories has spent recent weeks recovering from a September low. The stock found support near the $500 level — close to its 52-week low of $500.61 — before trending higher, with the latest available price around $557.97. Over the trailing 30 days, the shares have advanced by roughly 9%, a move that underscores improving sentiment but still leaves the stock far beneath its 52-week high of $769.98.
The rebound has coincided with a rotation back toward higher-quality, recurring-revenue names in the animal-health sector. IDEXX's diagnostics-led business model, which relies on instrument placements and consumable testing rather than discretionary pharmaceutical pricing, has positioned the company as a relative standout as investors weigh pricing pressures across the broader animal-health industry.
IDEXX Laboratories (IDXX) Business Overview and Competitive Position
IDEXX Laboratories is a global leader in pet healthcare innovation, developing and selling diagnostic instruments, consumables, reference laboratory services, and practice-management software for the veterinary market. Companion animal diagnostics account for the overwhelming majority of revenue, supplemented by water-quality testing and livestock, poultry, and dairy diagnostics. The company is a member of the S&P 500, employs roughly 11,000 people, and serves customers in more than 175 countries and territories.
IDEXX's competitive strength lies in a razor-and-blades model built around an installed base of analyzers and reference lab relationships that generate high-margin recurring testing revenue. Its expanding portfolio — including the inVue Dx cellular analyzer, the Cancer Dx screening menu, and cloud-based software — deepens customer switching costs and supports steady organic growth even amid soft clinic-visit trends.
Recent Developments Driving IDXX
Several verified developments have shaped investor sentiment toward IDEXX in recent weeks. The company's second-quarter results, reported in early August, exceeded expectations, with revenue of $1.22 billion up 9.7% year over year and adjusted earnings of $4.27 per share beating consensus. Management raised full-year guidance to revenue of $4.70 billion to $4.745 billion and earnings of $14.69 to $14.94 per share, reflecting 8.5% to 9.7% organic revenue growth.
On the analyst front, Jefferies reiterated a Buy rating on IDEXX in October while downgrading animal-health peers Zoetis and Elanco, arguing that diagnostics is better insulated from pharmaceutical pricing pressures. KeyBanc separately initiated coverage with a Sector Weight rating. IDEXX also expanded its AI capabilities through the acquisition of CoVetAI, an AI-powered clinical documentation and workflow platform for veterinary practices.
Looking ahead, IDEXX is scheduled to report third-quarter results on November 2, 2026, with consensus estimates near $3.70 in earnings per share on revenue of roughly $1.19 billion.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies appear in this section, helping users filter the broader marketplace for signals worth reviewing. These bots vary widely in strategy, timeframe, and performance metrics, so the section serves as a starting point for traders exploring automated approaches rather than a one-size-fits-all recommendation. Visitors can browse the featured robots to compare methodologies and assess which align with their own trading objectives.
2026 Outlook and What Investors Should Watch
The primary near-term catalyst is the third-quarter earnings release on November 2, 2026, along with any update to full-year guidance. Investors will be watching whether companion-animal diagnostic recurring revenue maintains its roughly 9% to 10% organic growth pace and how management frames U.S. same-store clinic-visit trends, which declined modestly in the second quarter.
Beyond earnings, key themes include the ongoing rollout of inVue Dx and Cancer Dx menu expansions, the integration of AI and software into clinical workflows, and the durability of pricing across the animal-health sector. Macroeconomic pressures on discretionary pet spending, foreign-exchange effects, and competitive dynamics in the diagnostics market also merit monitoring. As always, these factors carry both upside and downside risk and do not guarantee any particular outcome for the shares.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IDXX in upward trend: price rose above 50-day moving average on October 15, 2026
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IDXX as a result. In 54 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 21 of 41 cases over the following month. The odds of a continued upward trend are 51%.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 174 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for IDXX moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 15 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.040) is normal, around the industry mean (64.450). P/E Ratio (38.678) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties